Floatz logo

2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE

Schizophrenia

Taichung Veterans General HospitalSmall moleculePhase 4 / ApprovedDormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
65/ 100

Competitive context

142 Active assets in the Schizophrenia cohort.

Asset / SponsorPhaseRating
Xanomeline
European Group for Research In Schizophrenia
Phase 4BBB
Trospium
European Group for Research In Schizophrenia
Phase 4BBB
Asenapine
Noven Pharmaceuticals, Inc.
Phase 4BBB
Lurasidone
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
Brexpiprazole
Humanis Saglık Anonim Sirketi
Phase 4BBB

View all 50 →

Same molecule, other indications

2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE is also rated in:

central nervous system disorderDormant
B
Indicative · Phase 4
62 / 100
View asset →
physiological malfunction arising from mental factorDormant
B
Indicative · Phase 3
57 / 100
View asset →
anxiety disorderDormant
B
Indicative · Phase 3
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →